2018 Annual Corporate Presentation Successfully Held

2018 Annual Corporate Presentation Press Release

YungShin Global Holding Corporation Press Release

Release Date: September 27, 2018 

Contact Person: Li Yang-Zhe, Spokesperson

2018 Annual Corporate Presentation Successfully Held

YungShin Global Holding Corporation (TWSE: 3705) was invited to participate in the industry seminar organized by Yuanta Securities on September 20, 2018, at 2:00 PM. During the seminar, the company presented the development history of the YungShin Group, the company’s operational performance in the first half of 2018, and the future strategic plans of the group. The event also facilitated two-way communication and exchange of ideas with institutional investors. The atmosphere was lively, and the seminar concluded successfully at 3:00 PM.

In the first half of 2018, the company achieved consolidated revenue of NT$3,545,102 thousand, a 14.1% increase compared to NT$3,107,217 thousand in the same period last year. Pre-tax net income was NT$480,205 thousand, an increase of 29.73% compared to NT$369,761 thousand in the previous year. After-tax net income was NT$348,052 thousand, up 20.83% from NT$287,925 thousand in the same period last year. Earnings per share (EPS) were NT$1.30. The future development strategy of YungShin Group focuses on maximizing the value chain of the industry. The group plans to strengthen its competitiveness through vertical integration and horizontal expansion. By integrating resources along the supply chain, the group will continue to enhance vertical integration from raw materials and formulation to end-market sales. Furthermore, the company aims to integrate the pharmaceutical raw materials, formulation R&D, manufacturing, and sales processes.

The group will also solidify its presence in two major markets: the United States and China. The company is prepared to respond to the challenges posed by the China-U.S. trade war and to gain advantages in China's consistency evaluation. The integration of YungShin Group’s clinical trial companies in Taiwan and China will leverage the experience of Taiwan’s Hongyu and the equipment from Jiangsu Chongxin to gain an advantage in China's consistency evaluation.

The company will continue to expand horizontally in its four main business areas: active pharmaceutical ingredients (APIs), pharmaceutical formulations, consumer goods, and animal products. The group is focused on continuous investment, expansion, and mergers & acquisitions in these sectors.

YungShin Group hopes to rally like-minded partners domestically, uniting efforts to develop the global market. The group aims to share the benefits of the global pharmaceutical market through cooperation and joint ventures.